Publications by authors named "Dai Ya-Xin"
Article Synopsis
- A child tested positive for coronavirus through a stool sample, despite showing no symptoms.
- This positive test occurred 17 days after the child’s last exposure to the virus.
- The virus was found in stool samples for at least 9 more days, but respiratory tests came back negative.
Objectives: Severe fever with thrombocytopenia syndrome (SFTS) is an emerging tick-borne infectious disease caused by severe fever with thrombocytopenia syndrome virus (SFTSV). The seroprevalence of anti-SFTSV antibodies specific to SFTSV (IgG or IgM) has been investigated in different animal hosts in many epidemiological studies, but no systematic estimation of seroprevalence has yet been performed. Hence, this meta-analysis was conducted in order to obtain a more comprehensive result to clarify the prevalence of SFTSV in animals.
View Article and Find Full Text PDFArticle Synopsis
- Severe fever with thrombocytopenia syndrome (SFTS) is a new infectious disease caused by a bunyavirus, and a meta-analysis was conducted to clarify inconsistent results regarding its seroprevalence among the general population.
- The study analyzed data from 21 research articles, revealing an overall pooled seroprevalence of 4.3% for SFTSV antibodies in China, with regional variations and higher rates among farmers and individuals living close to SFTS patients.
- The findings indicate that seroprevalence is increasing since 2012, showing no significant differences by age or gender, and the results were confirmed to be robust through sensitivity analysis.
The role of ABC efflux pump, Rv1456c-Rv1457c-Rv1458c, from Mycobacterium tuberculosis clinical isolates in China.
Folia Microbiol (Praha)
November 2011
Recently the ATP-binding cassette (ABC) efflux pumps have been proved to be a major component of drug resistance in Mycobacterium tuberculosis. The objective of this study was to investigate the expression profiles of Rv1456c-Rv1457c-Rv1458c efflux system in clinical isolates of M. tuberculosis and its involvement in drug-resistance mechanisms.
View Article and Find Full Text PDF[A study on the treatment of chronic hepatitis B with YMDD mutation].
Zhonghua Gan Zang Bing Za Zhi
March 2009
Objective: To explore the strategy for the treatment of chronic hepatitis B with YMDD mutation.
Methods: A total of 120 chronic hepatitis B patients with YMDD mutation were randomly assigned into four groups. In group A, patients received adefovir dipivoxil for 48 weeks.